31-Oct-2026 17:29:54
SHREE GANESH REMEDIES Q2 FY27 ; NET PROFIT DOWN 67% AT ₹2 CR (YOY), UP 46% (QOQ)
REVENUE DOWN 23% AT ₹23 CR (YOY), UP 62% (QOQ) EBITDA DOWN 59% AT ₹4 CR (YOY), UP 17% (QOQ) MARGINS AT 16.9% VS 31.7% (YOY), 23.3% (QOQ)
Latest market headlines for SGRL on Terminal.
31-Oct-2026 17:29:54
REVENUE DOWN 23% AT ₹23 CR (YOY), UP 62% (QOQ) EBITDA DOWN 59% AT ₹4 CR (YOY), UP 17% (QOQ) MARGINS AT 16.9% VS 31.7% (YOY), 23.3% (QOQ)